In this episode of the Oncology Brothers podcast, Drs. Rohit & Rahul Gosain welcome Dr. Jacob Sands, a thoracic medical oncologist from the Dana-Farber Cancer Institute, to discuss the recent FDA approval of Dato-DXD (datopotamab deruxtecan) for previously treated EGFR-mutated non-small cell lung cancer (NSCLC). Key Topics:•⁠  ⁠Overview of Dato-DXd and its FDA approval•⁠  ⁠Mechanism of action and study design of the TROPION Lung trials•⁠  ⁠Efficacy and safety profile of Dato-DXd•⁠  ⁠Management of side effects and clinical pearls•⁠  ⁠Treatment sequencing for EGFR-mutated NSCLC Join us as we dive into the details of the TROPION Lung trials that led to this significant approval, the mechanism of action of Dato-DXd, and the implications for patients with various EGFR mutations. Dr. Sands shared insights on the study design, efficacy, and tolerability of this new antibody-drug conjugate, as well as important clinical pearls for managing side effects such as stomatitis, dry eyes, and interstitial lung disease (ILD).We also explored the current treatment landscape for EGFR-mutated NSCLC, including the sequencing of therapies and the potential role of Dato-DXd in clinical practice.Tune in for an informative discussion that highlights the exciting advancements in oncology and the hope they bring to patients. Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights into the world of oncology!